{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T21:15:07Z","timestamp":1783199707931,"version":"3.54.6"},"reference-count":53,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP21ak0101171"],"award-info":[{"award-number":["JP21ak0101171"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jpharmsci.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.xphs.2026.104292","type":"journal-article","created":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T15:21:55Z","timestamp":1776871315000},"page":"104292","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["A phospholipid-like charge-reversible lipid for PEG-free, stable, and low-inflammatory mRNA lipid nanoparticles"],"prefix":"10.1016","volume":"115","author":[{"given":"Peihan","family":"Sha","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sumika","family":"Maeshima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Koide","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soya","family":"Kanetaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoyuki","family":"Koge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9203-6988","authenticated-orcid":false,"given":"Toshio","family":"Kurosaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2388-4414","authenticated-orcid":false,"given":"Tomohiro","family":"Asai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.xphs.2026.104292_bib0001","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/s41541-020-0159-8","article-title":"The promise of mRNA vaccines: a biotech and industrial perspective","volume":"5","author":"Jackson","year":"2020","journal-title":"NPJ Vaccines"},{"issue":"9","key":"10.1016\/j.xphs.2026.104292_bib0002","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1517\/14712598.2015.1057563","article-title":"Modified mRNA as an alternative to plasmid DNA (pDNA) for transcript replacement and vaccination therapy","volume":"15","author":"Youn","year":"2015","journal-title":"Expert Opin Biol Ther"},{"issue":"4","key":"10.1016\/j.xphs.2026.104292_bib0003","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/nrd.2017.243","article-title":"Weissman D. mRNA vaccines - a new era in vaccinology","volume":"17","author":"Pardi","year":"2018","journal-title":"Nat Rev Drug Discov"},{"issue":"11","key":"10.1016\/j.xphs.2026.104292_bib0004","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1038\/s41573-021-00283-5","article-title":"mRNA vaccines for infectious diseases: principles, delivery and clinical translation","volume":"20","author":"Chaudhary","year":"2021","journal-title":"Nat Rev Drug Discov"},{"issue":"2","key":"10.1016\/j.xphs.2026.104292_bib0005","doi-asserted-by":"crossref","first-page":"622","DOI":"10.3390\/pharmaceutics15020622","article-title":"mRNA-based therapeutics in cancer treatment","volume":"15","author":"Sun","year":"2023","journal-title":"Pharmaceutics"},{"issue":"1","key":"10.1016\/j.xphs.2026.104292_bib0006","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/s12943-021-01335-5","article-title":"mRNA vaccine for cancer immunotherapy","volume":"20","author":"Miao","year":"2021","journal-title":"Mol Cancer"},{"key":"10.1016\/j.xphs.2026.104292_bib0007","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1016\/j.jconrel.2024.03.056","article-title":"mRNA therapies: pioneering a new era in rare genetic disease treatment","volume":"369","author":"Shen","year":"2024","journal-title":"J Control Release"},{"issue":"9","key":"10.1016\/j.xphs.2026.104292_bib0008","doi-asserted-by":"crossref","first-page":"2934","DOI":"10.1093\/brain\/awae135","article-title":"Unleashing the potential of mRNA therapeutics for inherited neurological diseases","volume":"147","author":"Monfrini","year":"2024","journal-title":"Brain"},{"issue":"12","key":"10.1016\/j.xphs.2026.104292_bib0009","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1038\/s41578-021-00358-0","article-title":"Lipid nanoparticles for mRNA delivery","volume":"6","author":"Hou","year":"2021","journal-title":"Nat Rev Mater"},{"issue":"1","key":"10.1016\/j.xphs.2026.104292_bib0010","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1038\/s41392-024-02002-z","article-title":"Progress and prospects of mRNA-based drugs in pre-clinical and clinical applications","volume":"9","author":"Shi","year":"2024","journal-title":"Signal Transduct Target Ther"},{"issue":"2","key":"10.1016\/j.xphs.2026.104292_bib0011","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.immuni.2005.06.008","article-title":"Suppression of RNA recognition by toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA","volume":"23","author":"Kariko","year":"2005","journal-title":"Immunity"},{"issue":"1","key":"10.1016\/j.xphs.2026.104292_bib0012","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1038\/s41392-022-00950-y","article-title":"Advances in COVID-19 mRNA vaccine development","volume":"7","author":"Fang","year":"2022","journal-title":"Signal Transduct Target Ther"},{"issue":"12","key":"10.1016\/j.xphs.2026.104292_bib0013","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.1038\/s41591-021-01583-4","article-title":"BNT162b2 and mRNA-1273 COVID-19 vaccine effectiveness against the SARS-CoV-2 Delta variant in Qatar","volume":"27","author":"Tang","year":"2021","journal-title":"Nat Med"},{"issue":"3","key":"10.1016\/j.xphs.2026.104292_bib0014","first-page":"1663","article-title":"COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer\/BioNTech and Moderna Vaccines","volume":"25","author":"Meo","year":"2021","journal-title":"Eur Rev Med Pharmacol Sci"},{"issue":"6","key":"10.1016\/j.xphs.2026.104292_bib0015","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.3390\/biomedicines10061260","article-title":"Immediate hypersensitivity reactions induced by COVID-19 vaccines: current trends, potential mechanisms and prevention strategies","volume":"10","author":"Hung","year":"2022","journal-title":"Biomedicines"},{"issue":"6","key":"10.1016\/j.xphs.2026.104292_bib0016","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1016\/S1473-3099(22)00054-8","article-title":"Safety of mRNA vaccines administered during the initial 6 months of the US COVID-19 vaccination programme: an observational study of reports to the Vaccine Adverse Event Reporting System and v-safe","volume":"22","author":"Rosenblum","year":"2022","journal-title":"Lancet Infect Dis"},{"issue":"25","key":"10.1016\/j.xphs.2026.104292_bib0017","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1056\/NEJMoa2027906","article-title":"Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates","volume":"383","author":"Walsh","year":"2020","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.xphs.2026.104292_bib0018","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1186\/s12951-022-01478-7","article-title":"Recent advances in mRNA-LNP therapeutics: immunological and pharmacological aspects","volume":"20","author":"Kiaie","year":"2022","journal-title":"J Nanobiotechnology"},{"issue":"1","key":"10.1016\/j.xphs.2026.104292_bib0019","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s11095-022-03460-2","article-title":"Structure and function of cationic and ionizable lipids for nucleic acid delivery","volume":"40","author":"Sun","year":"2023","journal-title":"Pharm Res"},{"issue":"8","key":"10.1016\/j.xphs.2026.104292_bib0020","doi-asserted-by":"crossref","DOI":"10.1002\/anbr.202300006","article-title":"Ionizable lipid nanoparticles for mRNA delivery","volume":"3","author":"Tang","year":"2023","journal-title":"Adv NanoBiomed Res"},{"issue":"12","key":"10.1016\/j.xphs.2026.104292_bib0021","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2021.103479","article-title":"The mRNA-LNP platform's lipid nanoparticle component used in preclinical vaccine studies is highly inflammatory","volume":"24","author":"Ndeupen","year":"2021","journal-title":"iScience"},{"issue":"1","key":"10.1016\/j.xphs.2026.104292_bib0022","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/s41541-021-00311-w","article-title":"mRNA-based SARS-CoV-2 vaccine candidate CVnCoV induces high levels of virus-neutralising antibodies and mediates protection in rodents","volume":"6","author":"Rauch","year":"2021","journal-title":"NPJ Vaccines"},{"issue":"10","key":"10.1016\/j.xphs.2026.104292_bib0023","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1038\/s12276-023-01086-x","article-title":"Immunogenicity of lipid nanoparticles and its impact on the efficacy of mRNA vaccines and therapeutics","volume":"55","author":"Lee","year":"2023","journal-title":"Exp Mol Med"},{"issue":"8","key":"10.1016\/j.xphs.2026.104292_bib0024","doi-asserted-by":"crossref","first-page":"11769","DOI":"10.1021\/acsnano.2c04543","article-title":"Anti-PEG antibodies boosted in humans by SARS-CoV-2 lipid nanoparticle mRNA vaccine","volume":"16","author":"Ju","year":"2022","journal-title":"ACS Nano"},{"key":"10.1016\/j.xphs.2026.104292_bib0025","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.jconrel.2021.11.042","article-title":"Anti-PEG antibodies compromise the integrity of PEGylated lipid-based nanoparticles via complement","volume":"341","author":"Estape Senti","year":"2022","journal-title":"J Control Release"},{"issue":"7","key":"10.1016\/j.xphs.2026.104292_bib0026","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1056\/NEJMra2035343","article-title":"Maintaining safety with SARS-CoV-2 vaccines","volume":"384","author":"Castells","year":"2021","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.xphs.2026.104292_bib0027","doi-asserted-by":"crossref","DOI":"10.1093\/nsr\/nwae135","article-title":"Minimizing the ratio of ionizable lipid in lipid nanoparticles for in vivo base editing","volume":"11","author":"Chen","year":"2024","journal-title":"Natl Sci Rev"},{"key":"10.1016\/j.xphs.2026.104292_bib0028","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.actbio.2022.09.065","article-title":"Development of amino acid-modified biodegradable lipid nanoparticles for siRNA delivery","volume":"154","author":"Patel","year":"2022","journal-title":"Acta Biomater"},{"key":"10.1016\/j.xphs.2026.104292_bib0029","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2025.125485","article-title":"Development of a messenger RNA vaccine using pH-responsive dipeptide-conjugated lipids exhibiting reduced inflammatory properties","volume":"674","author":"Matayoshi","year":"2025","journal-title":"Int J Pharm"},{"key":"10.1016\/j.xphs.2026.104292_bib0030","first-page":"86","article-title":"Engineering LNPs with polysarcosine lipids for mRNA delivery","volume":"37","author":"Kang","year":"2024","journal-title":"Bioact Mater"},{"issue":"17","key":"10.1016\/j.xphs.2026.104292_bib0031","doi-asserted-by":"crossref","first-page":"5854","DOI":"10.1039\/D1BM00570G","article-title":"Synthesis of poly(2-methacryloyloxyethyl phosphorylcholine)-conjugated lipids and their characterization and surface properties of modified liposomes for protein interactions","volume":"9","author":"Adler","year":"2021","journal-title":"Biomater Sci"},{"key":"10.1016\/j.xphs.2026.104292_bib0032","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2024.123871","article-title":"Recent progress on polySarcosine as an alternative to PEGylation: synthesis and biomedical applications","volume":"653","author":"Kabil","year":"2024","journal-title":"Int J Pharm"},{"issue":"12","key":"10.1016\/j.xphs.2026.104292_bib0033","doi-asserted-by":"crossref","first-page":"5654","DOI":"10.1021\/acs.biomac.3c00649","article-title":"Zwitterionic polymer-decorated lipid nanoparticles for mRNA delivery in mammalian cells","volume":"24","author":"Khunsuk","year":"2023","journal-title":"Biomacromolecules"},{"key":"10.1016\/j.xphs.2026.104292_bib0034","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2020.119479","article-title":"Charge-reversible lipid derivative: a novel type of pH-responsive lipid for nanoparticle-mediated siRNA delivery","volume":"585","author":"Hirai","year":"2020","journal-title":"Int J Pharm"},{"issue":"1","key":"10.1016\/j.xphs.2026.104292_bib0035","doi-asserted-by":"crossref","first-page":"9471","DOI":"10.1038\/s41467-024-53914-x","article-title":"Charge-assisted stabilization of lipid nanoparticles enables inhaled mRNA delivery for mucosal vaccination","volume":"15","author":"Liu","year":"2024","journal-title":"Nat Commun"},{"key":"10.1016\/j.xphs.2026.104292_bib0036","first-page":"2191","article-title":"Parameters and characteristics governing cellular internalization and trans-barrier trafficking of nanostructures","volume":"10","author":"Murugan","year":"2015","journal-title":"Int J Nanomedicine"},{"issue":"9","key":"10.1016\/j.xphs.2026.104292_bib0037","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1038\/s41551-021-00786-x","article-title":"Optimization of lipid nanoparticles for the delivery of nebulized therapeutic mRNA to the lungs","volume":"5","author":"Lokugamage","year":"2021","journal-title":"Nat Biomed Eng"},{"issue":"6","key":"10.1016\/j.xphs.2026.104292_bib0038","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1021\/acsmaterialsau.3c00032","article-title":"Lipid-based nanoparticles for drug\/gene delivery: an overview of the production techniques and difficulties encountered in their industrial development","volume":"3","author":"Mehta","year":"2023","journal-title":"ACS Mater Au"},{"issue":"18","key":"10.1016\/j.xphs.2026.104292_bib0039","doi-asserted-by":"crossref","first-page":"23208","DOI":"10.1016\/j.ceramint.2018.07.079","article-title":"A zeta potential and rheology study using electroacoustic spectroscopy on aqueous boron carbide suspensions","volume":"44","author":"Dawes","year":"2018","journal-title":"Ceram Int"},{"issue":"7830","key":"10.1016\/j.xphs.2026.104292_bib0040","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1038\/s41586-020-2622-0","article-title":"SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness","volume":"586","author":"Corbett","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.xphs.2026.104292_bib0041","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.948335","article-title":"Altering the mRNA-1273 dosing interval impacts the kinetics, quality, and magnitude of immune responses in mice","volume":"13","author":"Garcia-Dominguez","year":"2022","journal-title":"Front Immunol"},{"issue":"36","key":"10.1016\/j.xphs.2026.104292_bib0042","doi-asserted-by":"crossref","first-page":"24842","DOI":"10.1021\/acsnano.4c05088","article-title":"Lipid nanoparticles elicit reactogenicity and sickness behavior in mice via toll-like receptor 4 and myeloid differentiation protein 88 axis","volume":"18","author":"Korzun","year":"2024","journal-title":"ACS Nano"},{"issue":"1","key":"10.1016\/j.xphs.2026.104292_bib0043","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/s41541-025-01124-x","article-title":"Ionizable lipid nanoparticles of mRNA vaccines elicit NF-kappaB and IRF responses through toll-like receptor 4","volume":"10","author":"Zelkoski","year":"2025","journal-title":"NPJ Vaccines"},{"issue":"1","key":"10.1016\/j.xphs.2026.104292_bib0044","doi-asserted-by":"crossref","first-page":"224","DOI":"10.3390\/nu15010224","article-title":"Update on anti-inflammatory molecular mechanisms induced by oleic acid","volume":"15","author":"Santa-Maria","year":"2023","journal-title":"Nutrients"},{"key":"10.1016\/j.xphs.2026.104292_bib0045","doi-asserted-by":"crossref","DOI":"10.3389\/fphys.2021.668330","article-title":"Long chain fatty acids as modulators of immune cells function: contribution of FFA1 and FFA4 receptors","volume":"12","author":"Hidalgo","year":"2021","journal-title":"Front Physiol"},{"issue":"7","key":"10.1016\/j.xphs.2026.104292_bib0046","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1021\/acs.langmuir.2c02657","article-title":"Lipid nanoparticle and liposome reference materials: assessment of size homogeneity and long-term\u2212 70\u00b0C and 4\u00b0C storage stability","volume":"39","author":"Jakubek","year":"2023","journal-title":"Langmuir"},{"issue":"3","key":"10.1016\/j.xphs.2026.104292_bib0047","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1016\/j.xphs.2020.12.006","article-title":"Addressing the cold reality of mRNA vaccine stability","volume":"110","author":"Crommelin","year":"2021","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.xphs.2026.104292_bib0048","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.copbio.2021.09.016","article-title":"Principles for designing an optimal mRNA lipid nanoparticle vaccine","volume":"73","author":"Kon","year":"2022","journal-title":"Curr Opin Biotechnol"},{"issue":"1","key":"10.1016\/j.xphs.2026.104292_bib0049","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1186\/s12951-024-02812-x","article-title":"Role of size, surface charge, and PEGylated lipids of lipid nanoparticles (LNPs) on intramuscular delivery of mRNA","volume":"22","author":"Kong","year":"2024","journal-title":"J Nanobiotechnology"},{"key":"10.1016\/j.xphs.2026.104292_bib0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2022.114416","article-title":"The role of lipid components in lipid nanoparticles for vaccines and gene therapy","volume":"188","author":"Hald Albertsen","year":"2022","journal-title":"Adv Drug Deliv Rev"},{"issue":"12","key":"10.1016\/j.xphs.2026.104292_bib0051","doi-asserted-by":"crossref","first-page":"e139","DOI":"10.1038\/mtna.2013.66","article-title":"Influence of polyethylene glycol lipid desorption rates on pharmacokinetics and pharmacodynamics of siRNA lipid nanoparticles","volume":"2","author":"Mui","year":"2013","journal-title":"Mol Ther Nucleic Acids"},{"issue":"sup1","key":"10.1016\/j.xphs.2026.104292_bib0052","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1080\/10717544.2017.1388451","article-title":"Cleavable PEGylation: a strategy for overcoming the \"PEG dilemma\" in efficient drug delivery","volume":"24","author":"Fang","year":"2017","journal-title":"Drug Deliv"},{"issue":"46","key":"10.1016\/j.xphs.2026.104292_bib0053","doi-asserted-by":"crossref","first-page":"32045","DOI":"10.1021\/acsnano.4c10381","article-title":"Extracellular matrix limits nanoparticle diffusion and cellular uptake in a tissue-specific manner","volume":"18","author":"Cahn","year":"2024","journal-title":"ACS Nano"}],"container-title":["Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354926001413?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354926001413?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T20:21:53Z","timestamp":1783196513000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022354926001413"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":53,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S0022354926001413"],"URL":"https:\/\/doi.org\/10.1016\/j.xphs.2026.104292","relation":{},"ISSN":["0022-3549"],"issn-type":[{"value":"0022-3549","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A phospholipid-like charge-reversible lipid for PEG-free, stable, and low-inflammatory mRNA lipid nanoparticles","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xphs.2026.104292","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 American Pharmacists Association\u00ae. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"104292"}}